- About Us
- Services & Solutions
- Technologies
- Discovery
- Reagent Materials Generation
- Monoclonal Antibody Discovery
- Bispecific & Multispecific Antibody Generation
- Lead Optimization
- In Vitro Lead Characterization
- In Vivo Lead Characterization
- Other Molecular Modalities
- IND Filing Support
- Protein Sciences
- Protein Production
- Protein Analytics
- Bioinformatics
- Protein Sciences
- Mammalian
- Microbial
- mRNA
- Viral Vaccines
- WuXi XDC – Bioconjugation
- Testing
- Sustainability
- Careers
- Investors
- News & Resources
WuXi Biologics
Offering End-to-End Solutions
- About Us
About Us - Services & SolutionsAbout Us
- SustainabilityAbout Us
- CareersAbout Us
- InvestorsAbout Us
- News & ResourcesAbout Us
Scientific Poster Download
World ADC London 2023
An Integrated Approach to Accelerate the ADC Discovery, with Novel DAR Control and Developability Assessment Toolbox
Jiawei Lu, Qirui Fan, Jun Wang, Sudhir Patil, Wei Gu, George Wang, Lily Yin, and Jimmy Li
WuXi XDC
| Scientists constantly experience a lot of challenges during years of discovery process, such as fragmented CRO network, challenging conjugation, and analytical characterization for diversified moieties. Among those faced during discovery efforts for antibody-drug conjugates (ADCs), is the precise control of drug-to-antibody ratio (DAR) and drug distribution. WuXi XDC’s integrated bioconjugate discovery platform, WuXi DAR technology, includes antibody, linker-payload and ADC/bioconjugate preparation, developability assessment, proprietary narrow DAR distribution technology, and in vitro/in vivo characterization to precisely control the conjugate drug load to DAR2, DAR4 or DAR6. |  |
Notice:
You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?